MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202541046729 A) filed by Manipal Academy Of Higher Education on June 15, 2025, for A Compound And A Method For Inhibition Of Isocitrate Dehydrogenase Enzymes In Glioblastoma Cells.
Inventors include Vignesh Balaji E; and K. Sreedhara Ranganath Pai.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: The present invention relates to a compound N-(2-oxo-1,2,5,6,7,8-hexahydroquinolin-5-yl)thiane-4-carboxamide (100) comprising a hexahydroquinoline moiety (101) coupled to a thiane-4-carboxamide group (103) through an amide linkage, and an in vitro method of inhibiting the growth of glioblastoma cells using the compound N-(2-oxo-1,2,5,6,7,8-hexahydroquinolin-5-yl)thiane-4-carboxamide (100). The nitrogen heteroatom and sulfur heteroatom of the compound N-(2-oxo-1,2,5,6,7,8-hexahydroquinolin-5-yl)thiane-4- carboxamide (100) form hydrogen bonding and coordination interactions with the enzymatic binding sites of isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 enzymes simultaneously, blocking both cytoplasmic and mitochondrial D-2-hydroxyglutarate production pathways in glioblastoma cells. The in vitro method comprises seeding glioblastoma cells in a culture plate, administering the compound N-(2-oxo-1,2,5,6,7,8-hexahydroquinolin-5-yl)thiane-4-carboxamide (100) at a predetermined concentration, incubating the treated glioblastoma cells for a predetermined time period, and determining cell viability of the treated glioblastoma cells using a sulforhodamine B assay.
Disclaimer: Curated by HT Syndication.
